← All trials
NCT05508906
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Aug 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Aug 19, 2022
- Last posted
- Sep 26, 2022
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Olema Pharmaceuticals, Inc.Lead sponsor
- Olema Pharmaceuticals, Inc.Study director
- Olema Pharmaceuticals, Inc.Official
- NovartisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.